ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FBIO vs JNJ // EV/EBITDA & P/E VALUATION

Fortress Biotech Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: FBIO 3 — JNJ 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FBIO VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FBIO JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 66.90% 67.90% -1.00 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin 58.50% 28.50% +30.00 FBIO /net-margins <GO>
Revenue Growth (YoY) 9.70% 6.00% +3.70 FBIO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 1.00% 0.00% +1.00 FBIO /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.7 62.1 -23.41 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $66.7M $662.49B -$662.43B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FBIO REV JNJ REV FBIO GROSS % JNJ GROSS % FBIO FCF JNJ FCF
FY 2025 $63.3M $94.19B 66.9% 67.9% -$65.8M $19.70B
FY 2024 $57.7M $88.82B 63.8% 69.1% -$80.2M $19.84B
FY 2023 $84.5M $85.16B — — -$128.2M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FBIO // BETA —
JNJ // BETA 1.08